E

    Erasca Inc (ERAS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $17.88
    -0.15 (-0.83%)

    Market Cap: $6.31B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    62%(13/21)
    Avg Surprise
    -17.54%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.12
    Range$-0.14 - $-0.10
    7 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.12-1.9%
    60d ago$-0.12-1.9%
    30d ago$-0.12-1.9%
    7d ago$-0.12+1.2%
    Current$-0.12
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    Dec 31, 2026
    EPS Consensus$-0.51
    Range$-0.60 - $-0.40
    9 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.51---
    Sep 26EST
    		-$-0.12---
    Jun 26
    		$-0.14$-0.12-16.67%Miss-16.7%
    Mar 26
    		$-0.60$-0.23-160.87%Miss-445.5%
    Dec 25
    		$-0.10$-0.11+8.26%Beat+9.1%
    Sep 25
    		$-0.11$-0.11+0.00%Beat+0.0%
    Jun 25
    		$-0.12$-0.11-9.09%Miss+58.6%
    Mar 25
    		$-0.11$-0.13+15.38%Beat+52.2%
    Dec 24
    		$-0.11$-0.13+15.38%Beat+45.0%
    Sep 24
    		$-0.11$-0.17+35.29%Beat+45.0%
    Jun 24
    		$-0.29$-0.19-52.63%Miss-38.1%
    Mar 24
    		$-0.23$-0.20-15.00%Miss-4.5%
    Dec 23
    		$-0.20$-0.23+13.04%Beat+81.1%
    Sep 23
    		$-0.20$-0.22+9.09%Beat+31.0%
    Jun 23
    		$-0.21$-0.24+12.50%Beat+30.0%
    Mar 23
    		$-0.22$-0.31+29.03%Beat+29.0%
    Dec 22
    		$-1.06$-0.32-231.25%Miss-307.7%
    Sep 22
    		$-0.29$-0.31+6.45%Beat+37.0%
    Jun 22
    		$-0.30$-0.33+9.09%Beat+75.0%
    Mar 22
    		$-0.31$-0.30-3.33%Miss+58.4%
    Dec 21
    		$-0.26$-0.34+23.53%Beat+61.5%
    Sep 21
    		$-0.46$-0.64+28.13%Beat+51.9%
    Jun 21
    		$-1.20$-0.65-84.62%Miss-
    Mar 21
    		$-0.74$0.00N/AMiss-
    Dec 20
    		$-0.68$0.00N/AMiss-
    Dec 19
    		$-0.96$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-18.82EV/EBITDA-1.57x
    Price/FCF-56.76xFCF Yield-1.76%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-78.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio8.29xQuick Ratio8.29x
    Trading Statistics
    Beta0.65Avg Volume3.24M
    52-Week High$24.2852-Week Low$1.33

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$18.08
    SMA 20$18.20
    SMA 50$18.19
    SMA 200$12.57
    EMA 10$18.22
    EMA 20$18.20
    EMA 50$17.58
    EMA 200$13.09

    MACD

    Line: 0.07Signal: 0.08Hist: -0.01

    ADX

    ADX: 12.8+DI: 21.3-DI: 24.0

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down80.0
    PSAR$20.40

    Bollinger Bands

    Upper Band$19.27
    Lower Band$17.13
    %B Position1175%(Upper)
    Band Width0.35

    RSI (14-Day)

    Neutral
    48.1

    Momentum Oscillators

    Stoch %K45.1
    Stoch %D58.6
    Williams %R-71.6
    ROC (10d)-2.2%
    Momentum-0.40
    CCI (20d)-104.9
    MFI (14d)55.6

    Volatility Measures

    ATR (14d)$1.18(6.6%)
    StdDev (20d)0.53
    Hist Vol52.5%(High)

    Volume Flow

    VWAP$17.69
    OBV165.3M
    AD Line79.0M
    CMF (20d)-0.052

    Volume Metrics

    Avg Vol (20d)3.3M
    Vol Ratio1.5x
    VWMA (20d)$18.31

    Pivot Points

    R3$20.67
    R2$20.13
    R1$19.08
    Pivot Point$18.54
    S1$17.49
    S2$16.95
    S3$15.90

    Advanced Oscillators

    TSI1.89
    Ultimate Osc45.4
    KST-26.16

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$4.20M$0$0$0$5.58M$0
    Cost of Revenue$0$0$743,000$0$0$0$832,000$0$0$0$942,000$0
    Gross Profit$0$0$-743,000$0$0$0$-832,000$0$0$0$-942,000$0
    Operating Expenses$47.62M$187.91M$32.60M$34.55M$38.13M$35.63M$35.71M$37.24M$67.78M$38.85M$33.87M$34.66M
    R&D$35.90M$177.26M$23.24M$24.47M$28.67M$25.97M$26.12M$27.63M$55.53M$28.57M$24.80M$25.21M
    SG&A$11.72M$10.65M$9.36M$10.07M$9.46M$9.66M$9.59M$9.61M$12.25M$10.28M$9.07M$9.45M
    Operating Income$-47,619,000$-187,911,000$-32,604,000$-34,546,000$-38,125,000$-35,630,000$-35,712,000$-37,242,000$-67,782,000$-38,851,000$-33,872,000$-34,658,000
    Interest Income$3.60M$4.45M$3.57M$3.97M$4.33M$4.74M$5.28M$5.87M$5.04M$3.90M$4.24M$4.35M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-44,079,000$-183,440,000$-29,092,000$-30,612,000$-33,876,000$-30,966,000$-32,232,000$-31,200,000$-63,201,000$-35,017,000$-29,701,000$-30,361,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-44,079,000$-183,440,000$-29,092,000$-30,612,000$-33,876,000$-30,966,000$-32,232,000$-31,200,000$-63,201,000$-35,017,000$-29,701,000$-30,361,000
    EBITDA$-47,494,000$-187,912,000$-32,495,000$-34,850,000$-38,918,000$-36,870,000$-39,036,000$-38,745,000$-69,486,000$-40,261,000$-35,192,000$-36,136,000
    EBIT$-47,682,000$-187,889,000$-32,658,000$-34,583,000$-38,206,000$-35,706,000$-37,515,000$-37,069,000$-68,242,000$-38,917,000$-33,939,000$-34,707,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ERAS

    News

    BofA Securities Maintains Erasca(ERAS.US) With Hold Rating, Maintains Target Price $20

    BofA Securities has reiterated its Hold rating on Erasca (ERAS.US) and maintained its price target of $20. This indicates a continued neutral outlook on the company's stock performance by the financial institution.

    Moomoo•8/25/26•
    Neutral

    Erasca Receives FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Metastatic Pancreatic Cancer

    Erasca, Inc. has received FDA Fast Track Designation for ERAS-0015, an oral pan-RAS molecular glue, for treating metastatic pancreatic adenocarcinoma. This designation highlights the urgent need for new therapies in this difficult-to-treat cancer. Early clinical trials show encouraging activity for ERAS-0015, particularly in KRAS G12X pancreatic cancer, with plans for Phase 3 studies underway.

    Oncodaily•8/24/26•
    Bullish

    Erasca receives FDA fast track status for pancreatic cancer drug By Investing.com

    Erasca Inc. announced that the FDA has granted Fast Track Designation to its drug ERAS-0015 for metastatic pancreatic adenocarcinoma. This designation aims to expedite the development and review of therapies for serious conditions with unmet medical needs. Preliminary data from the AURORAS-1 Phase 1 trial showed a 57% overall response rate in patients with KRAS G12X pancreatic ductal adenocarcinoma treated with ERAS-0015 monotherapy.

    Investing.com•8/24/26•
    Bullish

    FDA fast tracks Erasca’s pan-RAS molecular glue after early pancreatic cancer responses

    The FDA has granted Fast Track Designation to Erasca's ERAS-0015, an oral pan-RAS molecular glue, for metastatic pancreatic adenocarcinoma. This designation follows promising Phase I data showing a 57% unconfirmed eight-week objective response rate in pancreatic cancer patients. The company plans to leverage this designation for further discussions with the FDA regarding a Phase III trial in pancreatic cancer and two additional registration-enabling trials in lung cancer, despite ongoing patent infringement and trade secret misappropriation claims.

    AllSci•8/24/26•
    Bullish

    Erasca receives FDA fast track status for pancreatic cancer drug

    Erasca Inc. (NASDAQ:ERAS) has been granted Fast Track Designation by the U.S. FDA for its drug ERAS-0015, intended for metastatic pancreatic adenocarcinoma. This designation aims to accelerate the development and review of the oral pan-RAS molecular glue, which has shown promising preliminary results in Phase 1 trials with a 57% overall response rate in KRAS G12X pancreatic cancer patients. Erasca plans several registration-enabling trials for pancreatic and lung cancers.

    Investing.com India•8/24/26•
    Bullish

    Frequently Asked Questions About ERAS

    Does ERAS pay dividends?
    Erasca Inc (ERAS) does not currently pay a regular dividend.
    What is ERAS's market cap?
    Erasca Inc (ERAS) has a market capitalization of $6.31B with a current stock price of $17.88.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In